Jump to content

Pegylated interferon

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Rlink2 (talk | contribs) at 01:58, 5 December 2021 (→‎top: archive link repair, may include: archive.* -> archive.today, and http->https for ghostarchive.org and archive.org (wp:el#Specifying_protocols)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Pegylated interferon (PEG-IFN) is a class of medication that includes three different drugs as of 2012:[1]

In these formulations, Polyethylene glycol (PEG) is added to make interferon last longer in the body.[3] They are used to treat both hepatitis B,[4] hepatitis C[1] and multiple sclerosis.[2]

Pegylated interferon is contraindicated in patients with hyperbilirubinaemia.

References

  1. ^ a b editor, Emilio Jirillo (2008). Hepatitis C virus disease : immunobiology and clinical applications ([Online-Ausg.] ed.). New York: Springer. p. 237. ISBN 978-0-387-71375-5. {{cite book}}: |last= has generic name (help)
  2. ^ a b Kieseier BC, Calabresi PA.; Calabresi (2012). "PEGylation of Interferon-β-1a: A Promising Strategy in Multiple Sclerosis". CNS Drugs. 26 (3): 205–14. doi:10.2165/11596970-000000000-00000. PMID 22201341. S2CID 34290702. Archived from the original on 2013-01-01.
  3. ^ Martin P (February 15, 2001). "Hepatology Focus: Update on Hepatitis C Treatment: Pegylated Interferon". medscape.
  4. ^ Dancygier H, Allescher HD (2010). Clinical Hepatology. [S.l.]: Springer Berlin Heidelberg. p. 765. ISBN 978-3-642-04509-7.